ClinicalTrials.gg
Status unknownNCT03167554Updated Mar 3, 2023

Ultrasound Guided Therapeutic Percutaneous Electrolysis in Achilles Tendinopathy.

An interventional study of Sham comparator and Experimental group 1 in Electrolysis, Achilles Tendinopathy and Ultrasonography, sponsored by Hospital Universitario Infanta Leonor. Status unknown at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-03.

Sponsored by Hospital Universitario Infanta Leonor · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Tendinopathy with a site in Spain — 9 open to participants now, 9 under way, none of them phase 3. Tendinopathy · Spain.

Planned enrollment
5th of 39
96 · median 60
Started
2023
with 6 others
No phase
35 of 42
8 open now
Registered
7th of 42
by date

Among the 42 studies in Tendinopathy with a site in Spain, this one is the 5th largest by planned enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2023, is one of 35 with no phase, and was the 7th registered.

Tendinopathy

399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

9 of the 42 studies in Tendinopathy with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Tendinopathy with a site in Spain, or all of them as a file.
02

Study summary

Achilles tendon is a frequent lower-limb tissue where tendinopathy may arise. Percutaneous Therapeutic Electrolysis (EPTE®) is an electronic device that enables to treat accurately, guided by an ultrasound, the tendon injured area by applying a galvanic current through an acupuncture needle. Thus, the first stage of physiological regenerative process may be obtained. Design: Randomized Controlled Clinical Trial. Objectives: To know the effectiveness of Percutaneous Therapeutic Electrolysis (EPTE®) versus a sham intervention at improving pain and function in patients who undergo Achilles Chronic Tendinopathy and to determine the efficiency of Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle versus Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle at improving pain and function in patients who undergo Achilles Chronic Tendinopathy. Participants: patients diagnosed with Achilles Chronic Tendinopathy. Setting. Infanta Leonor Hospital, Madrid, Spain. Experimental intervention: Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec versus bipolar needle. Sham intervention: the guide tube of the needle contacted with the skin and the device remained switched on to simulate its functioning.

Read the detailed description

Tendinopathy is a common injury among athletes, where the incidence reaches 50%. Nevertheless, industrial workers as well as sedentary subjects may also undergo this pain condition.

Achilles tendon is a frequent lower-limb tissue where tendinopathy may arise. Achilles tendinopathy risk factors have been detailed, such as: age, mechanical axis deviation of lower limbs, excessive training load dosage, and type of work activity. The middle portion of the tendon is the area where Achilles tendinopathy is most likely to be located. Interestingly, correlation between pain severity and the degree of tissue degeneration by imaging diagnosis is hardly showed in chronic tendinopathy conditions. Thus, chronic tendinopathy pain may be mediated not only by peripheral but by central mechanisms.

Percutaneous Therapeutic Electrolysis (EPTE® System; Manual EPTE, 2014 IONCLINICS \& DEIONIC, S.L.) is an electronic device that enables to treat accurately, guided by an ultrasound, the tendon injured area by penetrating the skin with an acupuncture needle. A galvanic current goes through the device to the needle so that the first stage of physiological regenerative process may be obtained. That is due to a chemical reaction that leads to a controlled alkaline burn into the injured tissue and a subsequent basification of extracellular medium. That elicits an inflammatory response; the destroyed tissue is metabolized by phagocytosis process. Design: Randomized Controlled Clinical Trial. Objectives: To know the effectiveness of Percutaneous Therapeutic Electrolysis (EPTE®) versus a sham intervention at improving pain and function in patients who undergo Achilles Chronic Tendinopathy, and to determine the efficiency of Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle versus Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle at improving pain and function in patients who undergo Achilles Chronic Tendinopathy. Participants: patients diagnosed with Achilles Chronic Tendinopathy. Setting. Infanta Leonor Hospital, Madrid, Spain. Experimental intervention: Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec versus bipolar needle. Sham intervention: the guide tube of the needle contacted with the skin and the electrolysis device remained switched on to simulate its functioning.

03

Conditions studied

  • Electrolysis
  • Achilles Tendinopathy
  • Ultrasonography
  • Physical Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Achilles Chronic Tendinopathy diagnosis (from 3months up to 3 years)

Exclusion criteria

Exclusion Criteria:

  • Physical therapy treatment within the last 4 months.
  • Surgery approach for Achilles tendinopathy.
  • Pregnancy
  • Corticoid treatment in the last 4 months.
  • Pacemaker
  • Thrombophlebitis
  • Systemic disease
  • Cognitive disease
  • Prosthesis or osteosynthesis
  • Dermatopathies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Sham comparator
    Sham group

    Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.

    Other: Sham comparator

  • Experimental
    Experimental group 1

    Electrolysis application with monopolar needle.

    Other: Experimental group 1

  • Experimental
    Experimental group 2

    Electrolysis application with bipolar needle.

    Other: Experimental group 2

Interventions

  • OtherSham comparator

    The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.

    Also known as: Sham group

  • OtherExperimental group 1

    Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.

    Also known as: Electrolysis application with monopolar needle.

  • OtherExperimental group 2

    Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.

    Also known as: Electrolysis application with bipolar needle.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Measured by Numeric Pain Rating Scale. Punctuation from 0 point up to 10 points. "0" no pain; "10" the most bearable pain.

    Time frame: 5 min

Secondary outcomes

  1. Lower limb functionality

    Measured by Visa-A Scale. Punctuation from 0 point up to 100 points. "0"point the most inability; "100" points complete functionality.

    Time frame: 10 min

  2. Achilles tendon thickening

    Assessed by ultrasonography. Thickening was considered when the thickness is 50% greater than the contralateral limb.

    Time frame: 5 min

  3. Length of the most thickened area

    Assessed by ultrasonography. Distance (in mm) between the two extremes of the thickened area

    Time frame: 5 min

  4. Location of the most thickened area

    Assessed by ultrasonography. Distance (in mm) from the Achilles insertion up to the thickening onset.

    Time frame: 5 min

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario Inflanta Leonor
    Madrid, Spain
    Recruiting
    • Javier Herraiz Garvin, MSc · Contactjavier.herraiz@salud.madrid.org · +34 687795607
    • Irene de la Rosa Diaz, Dr · Sub investigator
    • Ester Sanchez Rodriguez, MSc · Sub investigator
    • Rosalia de Dios Alvarez, Dr · Sub investigator
    • Natividad Plaza Andreu, Dr · Sub investigator
    • Manuel Benito Junquera, MSc · Sub investigator
    • Gema Lendinez Burgos, MSc · Sub investigator
    • Elena Barcina Garica, Dr · Sub investigator
    • Rosa Lorente Ramos, Dr · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Aug 2023, 6 months after the start.

Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's planned 6 months is below that.

Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 30, 2017
StartActual
Feb 28, 2023
Primary completionEst.
Aug 2023
CompletionEst.
Dec 2023
Last update
Mar 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03167554
Lead sponsor
Hospital Universitario Infanta Leonor
Responsible party
Sponsor
First posted
May 30, 2017
Start date
Feb 28, 2023
Primary completion
Aug 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 3, 2023

Study contacts

Javier Herraiz Garvin, MSc
Contact
javierherraizfisio@gmail.com
+34 687795607
Javier Herraiz Garvin, MSc
principal investigator · Hospital Universitario Infanta Leonor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion